Head and neck cancer is treated mainly by surgery and radiotherapy. Normal tissue toxicity due to x-ray exposure is a limiting factor for treatment success. Many efforts have been employed to develop predictive tests applied to clinical practice. Determination of lymphocyte radiosensitivity by radio-induced apoptosis arises as a possible method to predict tissue toxicity due to radiotherapy. »
01/28/10

The objective of this study was to conduct a cost−effectiveness evaluation of pemetrexed compared to docetaxel in the treatment of advanced or metastatic non−small cell lung cancer (NSCLC) for patients with predominantly non−squamous histology in the Spanish healthcare setting. »
01/29/10

rostate cancer is the second leading cause of cancer-related death in men. A typical feature of this disease is its ability to metastasize to bone. It is mainly osteosclerotic, and is caused by a relative excess of osteoblast activity, leading to an abnormal bone formation. Bone metastases are the result of a complex series of steps that are not yet fully understood and depend on dynamic crosstalk between metastatic cancer cells, cellular components of the bone marrow microenvironment, and bone matrix (osteoblasts and osteoclasts). »
01/27/10

The authors compared the types of treatments prostate cancer patients received from county hospitals and private providers as part of a statewide public assistance program. »
01/25/10

Positive lymph node (LN) status is considered a systemic disease state. In prostate cancer, LN−positive diagnosis during pelvic LN dissection (PLND) potentially leads to the abandonment of radical prostatectomy (RP). »
01/20/10

Previous reports suggested that bladder cancer patients who continue to smoke while receiving chemotherapy have poorer outcomes than their nonsmoking counterparts. Nicotine, the major addictive compound in cigarette smoke, is known to induce chemoresistance in some cancer cells. »
01/27/10

Urothelial carcinoma of the bladder is the second most common genitourinary malignancy and the second most common cause of genitourinary cancer−related deaths with a worldwide estimate of about 300,000 new cases diagnosed every year. »
09/14/09

To determine the difference in survival after cystectomy between patients presenting with primary muscle infiltrating bladder cancer and patients with progression to muscle infiltration after treatment for initial non−muscle−invasive bladder cancer (NMIBC). »
01/22/10

Treating patients with invasive transitional cell carcinoma of the bladder remains difficult due to the multiple biological behaviour patterns found in this disease. There is still controversy regarding the use of systemic treatment in invasive bladder carcinoma and the ideal moment for launching perioperative chemotherapy. We present an overview of current trends for systemic treatment of invasive bladder carcinoma. »
12/31/69

The potent anti−cancer capability of a novel CPT derivarate, 10−methoxy−9−nitrocamptothecin (MONCPT), has been demonstrated in our previous studies. The present study focuses on the in vitro and in vivo anti−cancer activities, the cell cycle arrest− and apoptosis−induction abilities of MONCPT on human bladder uroepithelial carcinoma 5637 cell line. »
12/06/09